Next Phase Newsletter

A venture capital firm founded in 2020 and headquartered in the US participates in Pre-Seed and Seed stage funding rounds to tech and science focused companies. The firm typically allocates $1M USD per company and will either lead or participate in a syndicate, though they prefer to lead. The firm invests globally. 
 
The firm invests in a wide range of sectors including, but not limited to, energy, robotics, life sciences, software services, education, and more. In terms of life sciences and healthcare, the firm is also agnostic and will look at therapeutics, medical devices, diagnostics, and digital health. If looking at medical devices, the firm prefers them to be AI and/or robotics driven. The firm does not look at single assets and rather prefers platform or technology driven assets. The firm is also indication-agnostic. Companies should be in development stages. 
 
The firm requires a full-time team. The firm also will take a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in Taiwan is firm overall is focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on is chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in Europe is solely focused on life sciences. The firm had a recent close on their fourth fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S. 
 
The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is not evaluating diagnostic technologies for the current fund. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases. 
 
The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2018 with offices in US and Asia. The firm invests in mainly Seed and Series A rounds, however, the firm is not stage-focused or valuation sensitive as their core focus is in return opportunities. The firm has around a 70-person global investment team that focuses on healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally, acting as a co-investor, making about 2-5 new portfolio investments each quarter and about 2-5 follow-on investments each quarter. Initial check sizes go up to $1M USD. 
 
As the firm is a generalist fund in terms of healthcare, the firm is looking for transformative technologies that shape the future. 
 
The firm values the founder’s vision to solve the most painful problems from the root cause with cost-effective solutions that can benefit large populations.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A healthcare-dedicated venture capital fund with offices in US and Europe is managed by a team of seasoned venture managers and entrepreneurs. The fund will make early-stage equity investments in preclinical and clinical-stage drug development companies. The investment size of the fund will range between USD 5-30 million per company. The fund prefers to invest in European-based companies, but exceptional opportunities in the US will also be considered. The fund has had its first closing and is actively seeking new investment opportunities. 
 
The firm is seeking to invest in innovative drug development companies. The fund has a special interest in biologics and is open to all indications including orphan indications. Generics, reformulations or second-use products (“micro-innovation”) are not part of the investment strategy. 
 
The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly established venture fund is currently fundraising for their newest fund and actively pursuing new investment opportunities that they can invest through their new fund. Typical check size is $2-5M, and the firm invests exclusively in therapeutics. The firm focuses on opportunities based in North America, Europe, and Israel. About 20% of their investments to date have been in Europe and Israel, while the rest have been in North America-based companies. 
 
The firm invests exclusively in therapeutics companies, and does not pursue medical devices, diagnostics, or digital health opportunities at this time. Within therapeutics, the firm is most interested in advanced therapeutics including genetic diseases, oncology/immuno-oncology, autoimmune, cardiovascular, ophthalmology, fibrosis, and rare/orphan diseases. The firm is least interested in neurodegenerative, infectious diseases, oligonucleotide, and epigenetic drugs, and does not consider reformulated or repurposed drugs. In terms of stage of development, the firm’s sweet spot is between late pre-clinical stage (after animal data) and Phase II. 
 
The firm seeks to invest in technologies backed by strong IP protection. To date, the firm has mostly led or co-led investment rounds, prefers to take an active stance in their portfolio companies, and requires a board seat. However, the firm is open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic corporate venture fund of a global pharmaceutical company actively invests in early-stage biotech companies that are of strategic interest to the parent pharmaceutical. The firm invests in global opportunities, but focuses primarily on North America and Europe. 
 
The firm invests in early-stage therapeutics and platform technology companies. The firm’s main areas of interest include immunology and inflammation, kidney disease including transplant, serious diseases treated in hospitals, neurodegenerative disease, and rare disease. Regarding platform technologies, the firm is interested in drug discovery technologies for small molecule, peptide, nucleic acid, and other novel modalities, delivery systems (CNS, kidney disease), and cell therapies (excluding those targeting oncology). The firm invests primarily in pre-clinical opportunities, and can consider those as early as discovery stage. The firm does not actively seek opportunities in medical devices, diagnostics, or digital health at this time. 
 
The firm has no specific company or management team requirements. The firm can help support companies beyond capital. The firm can offer scientific expertise, and is able to collaborate on early stage proof-of-concept experiments and projects with emerging companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.